Get the Stockscreener App
25.43
0.29%
0.085
Corvus Pharmaceuticals Inc stock is traded at $25.43, with a volume of 2.62M.
It is up +0.29% in the last 24 hours and up +247.28% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$25.52
Open:
$25.56
24h Volume:
2.62M
Relative Volume:
0.89
Market Cap:
$1.91B
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-45.42
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+217.95%
1M Performance:
+247.28%
6M Performance:
+448.06%
1Y Performance:
+382.92%
1-Day Range:
$25.49
$26.95
1-Week Range:
$12.69
$26.95
52-Week Range:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
25.51 | 1.91B | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results - Finviz
Corvus Pharmaceuticals - The Pharma Letter
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering - TipRanks
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains - MarketBeat
10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Are Hitting New Highs - Insider Monkey
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Jefferies raises Corvus Pharmaceuticals stock price target to $42 on strong AD data - Investing.com Canada
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Corvus Pharmaceuticals Prices Upsized Public Stock Offering - Eudaimonia and Co
Corvus Pharmaceuticals stock hits all-time high at 22.22 USD By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals launches $150 million public offering By Investing.com - Investing.com India
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials - Intellectia AI
Corvus Pharmaceuticals prices upsized public offering at $22.15 per share - Investing.com
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Yahoo Finance
Corvus Pharmaceuticals Announces Pricing of Upsized Underwritten Public Offering of Common Stock - Quiver Quantitative
Corvus Pharma raises $175M to advance lymphoma and atopic dermatitis trials - Stock Titan
Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer - TipRanks
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon (CRVS) - Seeking Alpha
Corvus Pharmaceuticals stock hits all-time high at 22.22 USD - Investing.com
Smart Money Is Betting Big In CRVS Options - Benzinga
Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge - TechStock²
Corvus Pharmaceuticals slides premarket after unveiling $150M equity raise - MSN
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know (CRVS) - Seeking Alpha
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Corvus Pharmaceuticals (CRVS) Is Up 229.4% After Strong Soquelitinib Data In Tough Dermatitis Patients - simplywall.st
Corvus Pharmaceuticals stock price target raised to $27 from $11 at H.C. Wainwright - Investing.com Canada
Corvus Pharmaceuticals Stock (CRVS) Opinions on Phase 1 Trial Results - Quiver Quantitative
Corvus Pharmaceuticals stock price target raised to $27 from $11 at H.C. Wainwright By Investing.com - Investing.com Australia
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge - TechStock²
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corvus Pharmaceuticals shares fall after announcing $150 million stock offering - Investing.com
Corvus Pharma Commences Public Offering Of $150 Mln Of Shares; Stock Down - Nasdaq
Corvus reports positive phase 1 data for atopic dermatitis drug By Investing.com - Investing.com India
Corvus Pharmaceuticals Stock Pre-Market (-5.9%): Announces $150M Public Offering - Trefis
Corvus Pharma stock dips over 6% after-hours following best day ever — what went wrong? - MSN
Corvus Pharmaceuticals Launches $150 Million Public Offering to Fund Clinical Trials - Intellectia AI
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Positive Soquelitinib Phase 1 Atopic Dermatitis Data - Yahoo Finance
Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong? - Stocktwits
Oppenheimer raises Corvus Pharmaceuticals stock price target to $32 on AD data - Investing.com
Corvus Pharmaceuticals Inc. (CRVS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off - TechStock²
Corvus Pharmaceuticals Inc Suspends Offering Of Common Stock Shares By & Between Co & Jefferies - TradingView — Track All Markets
Corvus Pharma stock falls after announcing $150 million offering - Investing.com
Corvus Pharma stock falls after announcing $150 million offering By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Launches $150M Stock Offering to Fund R&D and Capital Expenditures - Intellectia AI
Corvus Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants - TradingView — Track All Markets
Corvus Pharmaceuticals Suspends At-The-Market Equity Program - TipRanks
Corvus Pharmaceuticals launches $150 million public offering - Investing.com
Corvus Pharmaceuticals announces $150M common stock offering - TipRanks
Corvus Pharmaceuticals Initiates $150 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):